Literature DB >> 31394048

Lung Innate Lymphoid Cell Composition Is Altered in Primary Graft Dysfunction.

Laurel A Monticelli1,2, Joshua M Diamond3, Steven A Saenz2, Elia D Tait Wojno2, Mary K Porteous3, Edward Cantu4, David Artis2, Jason D Christie3.   

Abstract

Rationale: Primary graft dysfunction (PGD) is the leading cause of early morbidity and mortality after lung transplantation, but the immunologic mechanisms are poorly understood. Innate lymphoid cells (ILC) are a heterogeneous family of immune cells regulating pathologic inflammation and beneficial tissue repair. However, whether changes in donor-derived lung ILC populations are associated with PGD development has never been examined.
Objectives: To determine whether PGD in chronic obstructive pulmonary disease or interstitial lung disease transplant recipients is associated with alterations in ILC subset composition within the allograft.
Methods: We performed a single-center cohort study of lung transplantation patients with surgical biopsies of donor tissue taken before, and immediately after, allograft reperfusion. Donor immune cells from 18 patients were characterized phenotypically by flow cytometry for single-cell resolution of distinct ILC subsets. Changes in the percentage of ILC subsets with reperfusion or PGD (grade 3 within 72 h) were assessed.Measurements and Main
Results: Allograft reperfusion resulted in significantly decreased frequencies of natural killer cells and a trend toward reduced ILC populations, regardless of diagnosis (interstitial lung disease or chronic obstructive pulmonary disease). Seven patients developed PGD (38.9%), and PGD development was associated with selective reduction of the ILC2 subset after reperfusion. Conversely, patients without PGD exhibited significantly higher ILC1 frequencies before reperfusion, accompanied by elevated ILC2 frequencies after allograft reperfusion.Conclusions: The composition of donor ILC subsets is altered after allograft reperfusion and is associated with PGD development, suggesting that ILCs may be involved in regulating lung injury in lung transplant recipients.

Entities:  

Keywords:  chronic obstructive pulmonary disease; innate immune cell; interstitial lung disease; lung transplantation; primary graft dysfunction

Mesh:

Year:  2020        PMID: 31394048      PMCID: PMC6938146          DOI: 10.1164/rccm.201906-1113OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  49 in total

1.  Innate IL-13-producing nuocytes arise during allergic lung inflammation and contribute to airways hyperreactivity.

Authors:  Jillian L Barlow; Agustin Bellosi; Clare S Hardman; Lesley F Drynan; See Heng Wong; James P Cruickshank; Andrew N J McKenzie
Journal:  J Allergy Clin Immunol       Date:  2011-11-12       Impact factor: 10.793

Review 2.  Report of the International Society for Heart and Lung Transplantation Working Group on Primary Lung Graft Dysfunction, part II: Epidemiology, risk factors, and outcomes-A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation.

Authors:  Joshua M Diamond; Selim Arcasoy; Cassie C Kennedy; Michael Eberlein; Jonathan P Singer; Glenda M Patterson; Jeffrey D Edelman; Gundeep Dhillon; Tahuanty Pena; Steven M Kawut; James C Lee; Reda Girgis; John Dark; Gabriel Thabut
Journal:  J Heart Lung Transplant       Date:  2017-07-26       Impact factor: 10.247

3.  Transcriptionally defining ILC heterogeneity in humans.

Authors:  Gregory F Sonnenberg
Journal:  Nat Immunol       Date:  2016-04       Impact factor: 25.606

4.  Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161.

Authors:  Jenny M Mjösberg; Sara Trifari; Natasha K Crellin; Charlotte P Peters; Cornelis M van Drunen; Berber Piet; Wytske J Fokkens; Tom Cupedo; Hergen Spits
Journal:  Nat Immunol       Date:  2011-09-11       Impact factor: 25.606

5.  Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues.

Authors:  Jochem H Bernink; Charlotte P Peters; Marius Munneke; Anje A te Velde; Sybren L Meijer; Kees Weijer; Hulda S Hreggvidsdottir; Sigrid E Heinsbroek; Nicolas Legrand; Christianne J Buskens; Willem A Bemelman; Jenny M Mjösberg; Hergen Spits
Journal:  Nat Immunol       Date:  2013-01-20       Impact factor: 25.606

6.  Clinical risk factors for primary graft dysfunction after lung transplantation.

Authors:  Joshua M Diamond; James C Lee; Steven M Kawut; Rupal J Shah; A Russell Localio; Scarlett L Bellamy; David J Lederer; Edward Cantu; Benjamin A Kohl; Vibha N Lama; Sangeeta M Bhorade; Maria Crespo; Ejigayehu Demissie; Joshua Sonett; Keith Wille; Jonathan Orens; Ashish S Shah; Ann Weinacker; Selim Arcasoy; Pali D Shah; David S Wilkes; Lorraine B Ware; Scott M Palmer; Jason D Christie
Journal:  Am J Respir Crit Care Med       Date:  2013-01-10       Impact factor: 21.405

7.  CD4+ T lymphocytes mediate acute pulmonary ischemia-reperfusion injury.

Authors:  Zequan Yang; Ashish K Sharma; Joel Linden; Irving L Kron; Victor E Laubach
Journal:  J Thorac Cardiovasc Surg       Date:  2009-03       Impact factor: 5.209

8.  Human Innate Lymphoid Cell Subsets Possess Tissue-Type Based Heterogeneity in Phenotype and Frequency.

Authors:  Yannick Simoni; Michael Fehlings; Henrik N Kløverpris; Naomi McGovern; Si-Lin Koo; Chiew Yee Loh; Shawn Lim; Ayako Kurioka; Joannah R Fergusson; Choong-Leong Tang; Ming Hian Kam; Koh Dennis; Tony Kiat Hon Lim; Alexander Chung Yaw Fui; Chan Weng Hoong; Jerry Kok Yen Chan; Maria Curotto de Lafaille; Sriram Narayanan; Sonia Baig; Muhammad Shabeer; Sue-Anne Ee Shiow Toh; Henry Kun Kiaang Tan; Rosslyn Anicete; Eng-Huat Tan; Angela Takano; Paul Klenerman; Alasdair Leslie; Daniel S W Tan; Iain Beehuat Tan; Florent Ginhoux; Evan W Newell
Journal:  Immunity       Date:  2016-12-13       Impact factor: 43.474

9.  T cell contamination in flow cytometry gating approaches for analysis of innate lymphoid cells.

Authors:  Sara H Burkhard; Florian Mair; Kathrin Nussbaum; Sabrina Hasler; Burkhard Becher
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

10.  Ischemia of the lung causes extensive long-term pulmonary injury: an experimental study.

Authors:  Niels P van der Kaaij; Jolanda Kluin; Jack J Haitsma; Michael A den Bakker; Bart N Lambrecht; Burkhard Lachmann; Ron W F de Bruin; Ad J J C Bogers
Journal:  Respir Res       Date:  2008-03-26
View more
  10 in total

1.  Pulmonary Innate Lymphoid Cell Responses during Rhinovirus-induced Asthma Exacerbations In Vivo: A Clinical Trial.

Authors:  Jaideep Dhariwal; Aoife Cameron; Ernie Wong; Malte Paulsen; Maria-Belen Trujillo-Torralbo; Ajerico Del Rosario; Eteri Bakhsoliani; Tatiana Kebadze; Mark Almond; Hugo Farne; Leila Gogsadze; Julia Aniscenko; Batika M J Rana; Trevor T Hansel; David J Jackson; Onn Min Kon; Michael R Edwards; Roberto Solari; David J Cousins; Ross P Walton; Sebastian L Johnston
Journal:  Am J Respir Crit Care Med       Date:  2021-12-01       Impact factor: 30.528

2.  Ischemia reperfusion injury facilitates lung allograft acceptance through IL-33-mediated activation of donor-derived IL-5 producing group 2 innate lymphoid cells.

Authors:  Yizhan Guo; Zhongcheng Mei; Dongge Li; Anirban Banerjee; May A Khalil; Allen Burke; Jon Ritter; Christine Lau; Daniel Kreisel; Andrew E Gelman; Elizabeth Jacobsen; Irina G Luzina; Sergei P Atamas; Alexander Sasha Krupnick
Journal:  Am J Transplant       Date:  2022-05-17       Impact factor: 9.369

3.  Natural killer cells activated through NKG2D mediate lung ischemia-reperfusion injury.

Authors:  Daniel R Calabrese; Emily Aminian; Benat Mallavia; Fengchun Liu; Simon J Cleary; Oscar A Aguilar; Ping Wang; Jonathan P Singer; Steven R Hays; Jeffrey A Golden; Jasleen Kukreja; Daniel Dugger; Mary Nakamura; Lewis L Lanier; Mark R Looney; John R Greenland
Journal:  J Clin Invest       Date:  2021-02-01       Impact factor: 14.808

4.  ILC2 the Rescue?

Authors:  R Stokes Peebles
Journal:  Am J Respir Crit Care Med       Date:  2020-01-01       Impact factor: 21.405

Review 5.  Recent advances in our understanding of the allograft response.

Authors:  Conor Hennessy; Guido Lewik; Amy Cross; Joanna Hester; Fadi Issa
Journal:  Fac Rev       Date:  2021-02-25

Review 6.  Primary graft dysfunction: what we know.

Authors:  Emily Clausen; Edward Cantu
Journal:  J Thorac Dis       Date:  2021-11       Impact factor: 3.005

Review 7.  Heterogeneity of ILC2s in the Lungs.

Authors:  Masato Asaoka; Hiroki Kabata; Koichi Fukunaga
Journal:  Front Immunol       Date:  2022-06-09       Impact factor: 8.786

Review 8.  Lymphocytic Airway Inflammation in Lung Allografts.

Authors:  Jesse Santos; Daniel R Calabrese; John R Greenland
Journal:  Front Immunol       Date:  2022-07-12       Impact factor: 8.786

Review 9.  Recruited and Tissue-Resident Natural Killer Cells in the Lung During Infection and Cancer.

Authors:  Miriam Franklin; Emma Connolly; Tracy Hussell
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

10.  Donor leukocyte trafficking during human ex vivo lung perfusion.

Authors:  Andy Chao Hsuan Lee; Arianna Edobor; Thirushan Wigakumar; Maria Lysandrou; Laura K Johnston; Phillip McMullen; Vikranth Mirle; Ashley Diaz; Ryan Piech; Rebecca Rose; Martin Jendrisak; Diego di Sabato; Kumaran Shanmugarajah; John Fung; Jessica Donington; Maria Lucia Madariaga
Journal:  Clin Transplant       Date:  2022-04-18       Impact factor: 3.456

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.